Protocol.
This is a nonrandomized prospective trial in which all patients receive sirolimus, with their previous long-term clinical history used as their own control. The trial was registered at ClinicalTrials.gov (NCT02638389) and EudraCT (2015-001703-32) and started in January 2016.